Legacy Private Trust Co. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 43,340 shares of the company’s stock after selling 2,493 shares during the period. Legacy Private Trust Co.’s holdings in Johnson & Johnson were worth $5,259,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in JNJ. BlackRock Inc. lifted its holdings in shares of Johnson & Johnson by 4.7% during the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after acquiring an additional 7,853,141 shares during the period. Boston Partners lifted its holdings in shares of Johnson & Johnson by 68.7% during the 1st quarter. Boston Partners now owns 12,783,909 shares of the company’s stock worth $1,638,258,000 after acquiring an additional 5,207,124 shares during the period. Summit Trail Advisors LLC increased its position in shares of Johnson & Johnson by 11,692.6% during the 1st quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock worth $1,768,000 after purchasing an additional 1,752,841 shares in the last quarter. Mackenzie Financial Corp increased its position in shares of Johnson & Johnson by 55.1% during the 4th quarter. Mackenzie Financial Corp now owns 4,243,594 shares of the company’s stock worth $592,915,000 after purchasing an additional 1,507,278 shares in the last quarter. Finally, Flossbach Von Storch AG increased its position in shares of Johnson & Johnson by 100.1% during the 1st quarter. Flossbach Von Storch AG now owns 2,318,450 shares of the company’s stock worth $297,109,000 after purchasing an additional 1,159,690 shares in the last quarter. 66.62% of the stock is owned by institutional investors.

A number of brokerages recently issued reports on JNJ. Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 target price on shares of Johnson & Johnson in a research report on Friday, September 14th. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, July 15th. Credit Suisse Group set a $151.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, July 13th. Finally, Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research report on Thursday, July 12th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $142.87.

JNJ opened at $138.22 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $371.96 billion, a price-to-earnings ratio of 18.93, a P/E/G ratio of 2.20 and a beta of 0.69. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.04. The firm had revenue of $20.83 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.83 EPS. equities research analysts forecast that Johnson & Johnson will post 8.14 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th were given a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.60%. The ex-dividend date of this dividend was Monday, August 27th. Johnson & Johnson’s payout ratio is presently 49.32%.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 7,899 shares of the firm’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now owns 25,725 shares in the company, valued at approximately $3,528,955.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. Company insiders own 0.22% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Technical Analysis of Stocks and What It Means

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.